-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Merrimack Pharmaceuticals Inc quarterly/annual Earnings Per Share, Diluted history and growth rate from Q1 2011 to Q1 2024.
- Merrimack Pharmaceuticals Inc Earnings Per Share, Diluted for the quarter ending March 31, 2024 was 13.9 USD/shares.
- Merrimack Pharmaceuticals Inc Earnings Per Share, Diluted for the twelve months ending March 31, 2024 was 13.9 USD/shares.
- Merrimack Pharmaceuticals Inc annual Earnings Per Share, Diluted for 2023 was -0.08 USD/shares, a 27.3% increase from 2022.
- Merrimack Pharmaceuticals Inc annual Earnings Per Share, Diluted for 2022 was -0.11 USD/shares, a 38.9% increase from 2021.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)